SecSonar.com

Immunome, Inc. (IMNM)

Immunome, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Immunome, Inc. (IMNM) is a Biotechnology company based in US with a market capitalization of $2.1B. Revenue declined 23.2% year-over-year and free cash flow was negative at -$200.6M. This page tracks IMNM's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 131 employees · IPO Oct 2, 2020

Valuation

Valuation & price

$20.88 · as of May 17, 2026 · -22.6% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

3.33

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$26.97$17.68$8.40Jul 25Dec 25Jun 26Jul 7, 25$8.69Jul 9, 25$8.89Jul 11, 25$8.64Jul 15, 25$8.40Jul 17, 25$10.45Jul 21, 25$10.82Jul 23, 25$11.45Jul 25, 25$10.87Jul 29, 25$10.60Jul 31, 25$10.52Aug 4, 25$10.95Aug 6, 25$10.46Aug 8, 25$9.69Aug 12, 25$9.91Aug 14, 25$9.94Aug 19, 25$10.02Aug 21, 25$9.95Aug 25, 25$9.92Aug 27, 25$9.95Aug 29, 25$9.51Sep 3, 25$10.25Sep 5, 25$10.52Sep 9, 25$9.21Sep 11, 25$9.68Sep 15, 25$9.48Sep 17, 25$8.99Sep 19, 25$9.39Sep 23, 25$10.56Sep 25, 25$10.15Sep 29, 25$11.34Oct 2, 25$11.47Oct 6, 25$14.41Oct 8, 25$14.01Oct 10, 25$13.92Oct 14, 25$14.10Oct 16, 25$16.49Oct 20, 25$16.25Oct 22, 25$15.90Oct 24, 25$15.69Oct 28, 25$16.39Oct 30, 25$15.98Nov 3, 25$17.00Nov 5, 25$15.35Nov 7, 25$15.24Nov 11, 25$17.52Nov 14, 25$17.14Nov 18, 25$17.86Nov 20, 25$17.51Nov 24, 25$18.65Nov 26, 25$18.63Dec 1, 25$18.32Dec 3, 25$19.37Dec 5, 25$19.76Dec 9, 25$19.06Dec 11, 25$19.49Dec 15, 25$22.64Dec 17, 25$19.78Dec 19, 25$21.44Dec 23, 25$21.73Dec 26, 25$21.71Dec 31, 25$21.48Jan 5, 26$19.71Jan 7, 26$19.98Jan 9, 26$21.07Jan 13, 26$20.14Jan 15, 26$22.85Jan 20, 26$23.88Jan 22, 26$25.82Jan 26, 26$25.43Jan 28, 26$24.75Jan 30, 26$24.62Feb 3, 26$26.97Feb 5, 26$24.00Feb 9, 26$24.50Feb 11, 26$23.41Feb 17, 26$22.69Feb 19, 26$22.14Feb 23, 26$21.80Feb 25, 26$22.14Feb 27, 26$21.86Mar 3, 26$21.54Mar 5, 26$20.95Mar 9, 26$21.33Mar 11, 26$21.40Mar 13, 26$20.36Mar 17, 26$20.71Mar 19, 26$20.83Mar 23, 26$20.75Mar 25, 26$20.30Mar 27, 26$19.61Apr 1, 26$22.45Apr 6, 26$21.48Apr 8, 26$21.70Apr 10, 26$21.67Apr 14, 26$22.90Apr 16, 26$23.26Apr 20, 26$24.25Apr 22, 26$23.78Apr 24, 26$23.56Apr 28, 26$23.71Apr 30, 26$22.94May 4, 26$23.33May 6, 26$23.27May 8, 26$22.44May 12, 26$22.69May 15, 26$20.88May 19, 26$19.66May 21, 26$22.96May 26, 26$21.91May 28, 26$22.54Jun 1, 26$20.78Jun 3, 26$19.81Jun 5, 26$18.58Jun 9, 26$18.39Jun 11, 26$18.36Jun 15, 26$18.07Jun 17, 26$18.53Jun 22, 26$19.18Jun 24, 26$19.75Jun 30, 26$20.90
$8.4052-week range$26.97
Loading valuation history…

Fundamentals

Key fundamentals

$2.1B

Market cap

-23.2%

Revenue growth (YoY)

57.4%

Gross margin

-$200.6M

Free cash flow (USD)

-$649.6M

Net debt

Net cash position

49.0%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2018 → 2025

FY 2018$0.00FY 2019$0.00FY 2020$0.00FY 2021$0.00FY 2022$0.00FY 2023$14.0MFY 2024$9.0MFY 2025$6.9M
$0$6.9M

Free cash flow by year

2018 → 2025

FY 2018$-7.6MFY 2019$-9.8MFY 2020$-12.7MFY 2021$-18.3MFY 2022$-28.9MFY 2023$-8.4MFY 2024$-164.3MFY 2025$-200.6M
-$7.6M-$200.6M

Gross margin by year

2023 → 2025

FY 2023100.0%FY 2024100.0%FY 202557.4%
100.0%57.4%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

2

Insider buys · 90 days

3

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 12, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $4.4M · 10b5-1 PlanBarchas Isaac · Director · $4.4MJul 2, 2026Filing
  • Insider sellInsider Sell $1.1M · 10b5-1 PlanLechleider Robert · Chief Medical Officer · $1.1MJun 29, 2026Filing
  • Insider sellInsider Sell $1.1M · 10b5-1 PlanRosett Max · Chief Financial Officer · $1.1MJun 17, 2026Filing
  • 8-K eventAnnual Meeting ResultsJun 12, 2026Filing
  • Insider buyInsider Buy $204KBIENAIME JEAN JACQUES · Director · $204.3KJun 9, 2026Filing
  • Insider buyInsider Buy $104KBIENAIME JEAN JACQUES · Director · $103.5KMay 19, 2026Filing
  • 8-K eventEarnings ReleaseMay 12, 2026Filing
  • Quarterly report10-Q FiledMay 12, 2026Filing
  • Insider sellInsider Sell $1.4M · 10b5-1 PlanRosett Max · Chief Financial Officer · $1.4MApr 3, 2026Filing
  • Insider sellInsider Sell $204K · 10b5-1 PlanHiggins Jack · Chief Scientific Officer · $204.2KApr 3, 2026Filing

Questions

Frequently asked questions

What is Immunome, Inc.'s market cap?

Immunome, Inc. (IMNM) has a market capitalization of $2.1B.

What is IMNM's P/E ratio?

A meaningful P/E ratio is not available for IMNM — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is IMNM's price-to-book (P/B) ratio?

IMNM trades at 3.33 times book value per share.

Are insiders buying IMNM stock?

Yes — SEC Form 4 filings show 2 open-market insider buys and 3 sells at Immunome, Inc. in the last 90 days.

Same arena

Related companies in Biotechnology

CLDX

Celldex Therapeutics, Inc.

$2.1B

NBTX

Nanobiotix S.A.

$2B

OCUL

Ocular Therapeutix, Inc.

$2B

ZLAB

Zai Lab Limited

$2B

MESO

Mesoblast Limited

$2B

AUPH

Aurinia Pharmaceuticals Inc.

$2B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.